10,310 Shares in Exelixis, Inc. $EXEL Acquired by Global Retirement Partners LLC

Global Retirement Partners LLC purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 10,310 shares of the biotechnology company’s stock, valued at approximately $561,000.

Other institutional investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp acquired a new position in Exelixis in the second quarter worth $107,803,000. Focus Partners Advisor Solutions LLC bought a new position in shares of Exelixis in the second quarter valued at about $1,447,000. GSA Capital Partners LLP bought a new position in shares of Exelixis in the second quarter valued at about $269,000. Annex Advisory Services LLC acquired a new position in Exelixis during the 2nd quarter worth about $1,410,000. Finally, Tema ETFs LLC lifted its position in Exelixis by 0.7% during the 2nd quarter. Tema ETFs LLC now owns 96,885 shares of the biotechnology company’s stock worth $5,272,000 after buying an additional 627 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling at Exelixis

In related news, Director Mary C. Beckerle sold 9,812 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $53.66, for a total transaction of $526,511.92. Following the completion of the sale, the director directly owned 16,079 shares of the company’s stock, valued at $862,799.14. The trade was a 37.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack L. Wyszomierski sold 3,925 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $50.55, for a total transaction of $198,408.75. Following the completion of the transaction, the director owned 284,384 shares in the company, valued at $14,375,611.20. This represents a 1.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 67,000 shares of company stock worth $3,404,652 in the last 90 days. Corporate insiders own 2.60% of the company’s stock.

Exelixis Stock Up 1.5%

Exelixis stock opened at $53.12 on Wednesday. The business’s 50-day simple moving average is $54.20 and its 200 day simple moving average is $48.35. The stock has a market cap of $13.16 billion, a price-to-earnings ratio of 16.70, a P/E/G ratio of 1.53 and a beta of 0.44. Exelixis, Inc. has a 12-month low of $33.76 and a 12-month high of $57.57.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.06. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The firm had revenue of $628.69 million during the quarter, compared to analysts’ expectations of $636.40 million. During the same period in the previous year, the business posted $0.75 EPS. The company’s quarterly revenue was up 10.6% compared to the same quarter last year. As a group, sell-side analysts expect that Exelixis, Inc. will post 3.18 EPS for the current year.

Wall Street Analyst Weigh In

EXEL has been the topic of a number of research analyst reports. UBS Group set a $55.00 price objective on shares of Exelixis in a report on Monday, August 3rd. Weiss Ratings raised shares of Exelixis from a “buy (b)” rating to a “buy (a-)” rating in a research note on Tuesday, August 11th. Leerink Partners lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and set a $52.00 target price on the stock. in a research report on Thursday, August 6th. Citizens Jmp increased their price target on shares of Exelixis from $50.00 to $55.00 and gave the company a “market outperform” rating in a research note on Wednesday, June 24th. Finally, Wall Street Zen lowered shares of Exelixis from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Exelixis currently has an average rating of “Hold” and a consensus target price of $50.07.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.